Oxo substituents markedly alter the phase II metabolism of α- hydroxybutenylbenzenes: Models probing the bioactivation mechanisms of tamoxifen

Chemical Research in Toxicology

Volumn 10, Issue 8, 1997, Pages 887-894

  Ramakrishna, Kornepati V ^a   Fan, Peter W ^a   Boyer, C Scott ^b   Dalvie, Deepak ^b   Bolton, Judy L ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZENE DERIVATIVE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HYDROXYTAMOXIFEN; TAMOXIFEN;

ANIMAL TISSUE; ARTICLE; BREAST CANCER; CANCER HORMONE THERAPY; CANCER RISK; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DNA ADDUCT; DRUG CONJUGATION; DRUG STRUCTURE; LIVER CARCINOMA; LIVER CYTOSOL; MALE; NONHUMAN; RAT;

ANIMALS; BIOTRANSFORMATION; ESTROGEN ANTAGONISTS; GLUTATHIONE; LIVER; MALE; RATS; RATS, SPRAGUE-DAWLEY; SULFOTRANSFERASES; TAMOXIFEN;

ANIMALIA;

EID: 0030851640     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx970060r     Document Type: Article

References (32)

1. Furr, B. J. A., and Jordan, V. C. (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol. Ther. 25, 127-205.
2. Fisher, B., and Redmond, C. (1991) New perspective on cancer of the contralateral breast: a marker for assessing tamoxifen as a preventive agent. J. Natl. Cancer Inst. 83, 1278-1280.
3. King, C. M. (1994) Tamoxifen and induction of cancer. Carcino-genesis 16, 1449-1454.
4. Williams, G. M., Iatropoulos, M. J., Djordjevic, M. W., and Kaltenberg, O. P. (1993) The triphenylethylene drug tamoxifen is a strong carcinogen in the rat. Carcinogenesis 14, 315-317.
5. Fendel, K. C., and Zimniski, S. J. (19921 Role of tamoxifen in the induction of hormone-independent rat mammary tumors. Cancer Res. 52, 235-237.
6. Killackey, M. A., Hakes, T. B., and Price, V. K. (1985) Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat. Rep. 69, 237-238.
7. Fornander, T., Cedermark, B., Matteson, A., Skoog, L., Theve, T., Askergren, J., Rutqvist, I. E., Glas, U., Silljverswaard, C., Somell, A., Wilking, N., and Hjolmar, M. J. (1989) Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet 1, 117-119.
8. Hemminki, K., Rajaniemi, H., Lindahl, B., and Moberger, B. (1996) Tamoxifen-induced DNA adducts in endometrial samples from breast cancer patients. Cancer Res. 56, 4374-4377.
9. Henderson, B. E., Ross, R., and Bernstein, L. (1988) Estrogens as a cause of human cancer: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res. 48, 246-253.
10. Potter, G. A., McCague, R., and Jarman, M. (1994) A mechanistic hypothesis for DNA adduct formation by tamoxifen following hepatic oxidative metabolism. Carcinogenesis 5, 439-442.
11. Moorthy, B., Sriram, P., Pathak, D. N., Bodell, W. J., and Randerath, K. (1996) Tamoxifen metabolic activation: Comparison of DNA adducts formed by microsomal and chemical activation of tamoxifen and 4-hydroxytamoxifen with DNA adducts formed in vivo. Cancer Res. 56, 53-57.
12. 32P-postlabeling and use of metabolic inhibitors for two distinct pathways leading to mouse hepatic DNA adduct formation and identification of 4-hydroxytamoxifen as a proximate metabolite. Carcinogenesis 15, 2087-2094.
13. White, I. N. H., de Matteis, F., Davies, A., Smith, L. L., Crofton-Sleigh, C., Venitt, S., Hewer, A., and Phillips, D. H. (1992) Genotoxic potential of tamoxifen and analogues in female Fisher F344/n rats, DBA/2 and C57BL/6 and in human MCL-5 cells. Carcinogenesis 13, 2197-2203.
14. 5-ethyl]-tamoxifen implicates α-hydroxylation of the ethyl group as a major pathway of tamoxifen activation to a liver carcinogen. Carcinogenesis 15, 1487-1492.
15. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J., and Poon, G. K. (1994) α-Hydroxytamoxifen, a metabolite of tamoxifen with exceptionally high DNA-binding activity in rat hepatocytes. Cancer Res. 54, 5518-5522.
16. Phillips, D. H., Carmichael, P. L., Hewer, A., Cole, K. J., Hardcastle, I. R., Poon, G. K., Keogh, A., and Strain, A. J. (1996) Activation of tamoxifen and its metabolite α-hydroxytamoxifen to DNA-binding products: comparisons between human, rat and mouse hepatocytes. Carcinogenesis 17, 89-94.
17. Hard, G. C., Iatropoulos, M. J., Jordan, K., Radi, L., Kaltenberg, O. P., Imondi, A. R., and Williams, G. M. (1993) Major Difference in the Hepatocarcinogenicity and DNA Adduct Forming Ability between Toremifene and Tamoxifen in Female Crl:CD(BR) Rats. Cancer Res. 53, 4534-4541.
18. Surh, Y., Kwon, H., and Tannenbaum, S. R. (1993) Sulfotransferase-mediated activation of 4-hydroxy-and 3,4-dihydroxy-3,4-dihydrocyclopenta[c,d]pyrene, major metabolites of cyclopenta-[c,d]pyrene. Cancer Res. 53, 1017-1022.
19. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951) Protein measurement with the folin-phenol reagent. J. Biol. Chem. 193, 265-275.
20. Bolton, J. L., Comeau, E., and Vukomanovic, V. (1995) The influence of 4-alkyl substituents on the formation and reactivity of 2-methoxy-quinone methides: Evidence that extended π-conjugation dramatically stabilizes the quinone methide formed from eugenol. Chem.-Biol. Interact. 95, 279-290.
21. Bolton, J. L., Acay, N. M., and Vukomanovic, V. (1994) Evidence that 4-allyl-ortho-quinones spontaneously rearrange to their more electrophilic quinone methides: Potential bioactivation mechanism for the hepatocarcinogen safrole. Chem. Res. Toxicol. 7, 443-450.
22. Moorthy, B., and Randerath, K. (1996) Pentachlorophenol enhances 9-hydroxybenzo[a]pyrene-induced hepatic DNA adduct formation in vivo and inhibits microsomal rpoxide hydrolase and glutathione S-transferase activities in vitro: likely inhibition of epoxide detoxication by pentachlorophenol. Arch. Toxicol. 70, 696-703.
23. Chasseaud, L. F. (1979) The role of glutathione and glutathione S-transferases in the metabolism of chemical carcinogens and other electrophilic agents. Adv. Cancer Res. 29, 175-274.
24. Pathak, D. N., and Bodell, W. J. (1994) DNA adduct formation by tamoxifen with rat and human liver microsomal activation systems. Carcinogenesis 15, 529-532.
25. Pathak, D. N., Pongracz, K., and Bodell, W. J. (1995) Microsomal and peroxidase activation of 4-hydroxytamoxifen to form DNA adducts: Comparison with DNA adducts formed in Sprague-Dawley rats treated with tamoxifen. Cancinogenesis 16, 11-15.
26. Osborne, M. R., Hewer, A., Hardcastle, I. R., Carmichael, P. L., and Phillips, D. H. (1996) Identification of the major tamoxifendeoxyguanosine adduct formed in the liver DNA of rats treated with tamoxifen. Cancer Res. 56, 66-71.
27. Lowry, T. H., and Richardson, K. S. (1987) Mechanism and theory in organic chemistry, 3rd ed., p 144, Harper & Row, New York.
28. Kuramochi, H. (1996) Conformational studies and electronic structures of tamoxifen and toremifene and their allylic carbocations proposed as reactive intermediates leading to DNA adduct formation. J. Med. Chem. 39, 2877-2886.
29. Robertson, C. A., Seymour, J. L., Hsia, M. T., and Allen, J. R. (1977) Covalent interaction of dehydroretronecine, a carcinogenic metabolites of the pyrrolizidine alkaloid monocrotaline, with cysteine and glutathione. Cancer Res. 37, 3141-3144.
30. Tajima, K., Yamamoto, K., and Mizutani, T. (1985) Formation of a glutathione conjugate from butylated hydroxytoluene by rat liver microsomes. Biochem. Pharmacol. 34, 2109-2114.
31. Saito, K., Shinohara, A., Kamataki, T., and Kato, R. (1985) Metabolic activation of mutagenic N-hydroxyarylamines by O-acetyltransferase in Salmonella tryphimurium TA98. Arch. Biochem. Biophys. 239, 286-295.
32. Malfatti, M. A., Connors, M. S., Mauthe, R. J., and Felton, J. S. (1996) The capability of rat colon tissue slices to metabolize the cooked-food carcinogen 2-amino-1-methyl-6-phenylimidazol[4,5-b] pyridine. Cancer Res. 56, 2550-2555.